Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-mo... Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0046 | 1.17827868852 | 0.3904 | 0.8699 | 0.01 | 3349 | 0.35291275 | CS |
| 4 | -0.075 | -15.9574468085 | 0.47 | 0.8699 | 0.01 | 4002 | 0.38086407 | CS |
| 12 | -0.525 | -57.0652173913 | 0.92 | 0.92 | 0.01 | 4195 | 0.46741679 | CS |
| 26 | 0.045 | 12.8571428571 | 0.35 | 1.12 | 0.01 | 17405 | 0.52398786 | CS |
| 52 | 0.045 | 12.8571428571 | 0.35 | 1.12 | 0.01 | 17405 | 0.52398786 | CS |
| 156 | 0.045 | 12.8571428571 | 0.35 | 1.12 | 0.01 | 17405 | 0.52398786 | CS |
| 260 | 0.045 | 12.8571428571 | 0.35 | 1.12 | 0.01 | 17405 | 0.52398786 | CS |
watcher777
2分前
fuagf
4分前
tisdal
4分前
Lazy Oaks
4分前
jimr1717
6分前
Hey_Its_That_Guy
7分前
Flip it
8分前
SSKILLZ1
14分前
starric
18分前
oilsleuth
22分前
catsu1
22分前
Large Green
25分前
okpj
26分前
Walter4
27分前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。